Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 11/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 2/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | GCG | P01275 | 3/20 | 0.30 |
| ▸ | GIPR | P48546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647808 | 0.87 | GCGR (0.38) | GCGRGCG | |
| SCHEMBL6914041 | 0.82 | GCGR (0.36) | GCGRCYP2D6EPHX2PPARDGIPR | |
| SCHEMBL2653731 | 0.77 | HAO1 (0.46) | GCGRCYP2D6EPHX2PPARD | |
| SCHEMBL6755519 | 0.76 | GCGR (0.55) | GCGRGLP1ROPRM1OPRK1GIPR | |
| SCHEMBL6917335 | 0.74 | DHODH (0.39) | GCGRCYP2D6EPHX2GLP1RPPARD | |
| SCHEMBL2654474 | 0.73 | HAO1 (0.42) | GCGRCYP2D6EPHX2PPARD | |
| SCHEMBL2647125 | 0.73 | CYP2D6 (0.45) | GCGRCYP2D6GLP1ROPRM1OPRK1 | |
| SCHEMBL2660182 | 0.73 | GCGR (0.45) | GCGRCYP2D6OPRM1OPRK1GCG | |
| SCHEMBL2647568 | 0.73 | GCGR (0.45) | GCGRCYP2D6OPRM1OPRK1GCG | |
| SCHEMBL2647399 | 0.72 | PPARD (0.47) | GCGRGLP1RPPARDGCGGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885CYP2D6 2704/4885EPHX2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.